Vanguard Group Inc Dia Medica Therapeutics Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,017,402 shares of DMAC stock, worth $4.48 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,017,402
Previous 1,013,522
0.38%
Holding current value
$4.48 Million
Previous $2.81 Million
6.91%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding DMAC
# of Institutions
36Shares Held
3.87MCall Options Held
1.3KPut Options Held
1K-
First Manhattan CO New York, NY839KShares$3.69 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX483KShares$2.12 Million3.48% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.68 Million0.41% of portfolio
-
Geode Capital Management, LLC Boston, MA237KShares$1.04 Million0.0% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA169KShares$742,4120.62% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $116M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...